Potential market catalysts in the first quarter of 2018 include important top-line clinical trial results for rigerimod (developed by ImmuPharma and SymBio) for systemic lupus…

Para acessar a publicação na íntegra clique aqui

Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 17 | JANUARY 2018